ERBB2 and breast cancer: A83-01 (Table 1), another small molecule inhibitor, was suggested to modulate the TGF-β/SMAD pathway and prevent the development of a mesenchymal phenotype in HER2+ BC cells, thus enhancing the cell response to trastuzumab treatment [100].